CVS Health’s second quarter was marked by better-than-expected revenue and profit, but investor sentiment was dampened by rising concerns over sustainability of these results. Management cited strong performance across all business segments, particularly from specialty pharmacy and Medicare Advantage, as key drivers. CEO David Joyner acknowledged, “the cumulative impact of these actions [in Aetna and Caremark] is starting to come through clearly in our results.” However, management also highlighted pockets of pressure, such as ongoing challenges in the 340B program and the normalization of script share gains from Rite Aid.
Is now the time to buy CVS? Find out in our full research report (it’s free for active Edge members).
CVS Health (CVS) Q2 CY2026 Highlights:
- Revenue: $106.1 billion vs analyst estimates of $99.41 billion (7.3% year-on-year growth, 6.7% beat)
- Adjusted EPS: $2.58 vs analyst estimates of $1.85 (39.4% beat)
- Adjusted Operating Income: $5.16 billion vs analyst estimates of $3.95 billion (4.9% margin, 30.6% beat)
- Management raised its full-year Adjusted EPS guidance to $8 at the midpoint, a 8.1% increase
- Operating Margin: 4.4%, up from 2.4% in the same quarter last year
- Locations: 8,931.1 at quarter end, down from 8,999 in the same quarter last year
- Same-Store Sales rose 2.6% year on year (15.4% in the same quarter last year)
- Market Capitalization: $119.6 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From CVS Health’s Q2 Earnings Call
- Michael Cherny (Leerink Partners) asked about the ability to offset 340B headwinds in Health Services. CFO Brian Newman reiterated confidence in enterprise earnings growth, while President Prem Shah pointed to specialty pharmacy and biosimilars as mitigating factors.
- Lisa Gill (JPMorgan) questioned the sustainability of Aetna’s improved margins and the long-term opportunity from GLP-1 drugs. Head of Aetna Steven Nelson emphasized Medicare Advantage momentum, and Joyner noted both funded and direct-to-consumer GLP-1 channels as growth drivers.
- Justin Lake (Wolfe Research) probed on the durability of pharmacy growth as Rite Aid share gains normalize. Prem Shah described investments in service, technology, and the CostVantage model as drivers of future stability.
- Stephen Baxter (Wells Fargo) asked about commercial insurance margins and the impact of the No Surprises Act. Nelson explained that pricing discipline and technology solutions have kept the commercial business in line, despite challenges in dispute resolution processes.
- Erin Wilson Wright (Morgan Stanley) sought detail on AI and technology investment cadence. Joyner and Nelson described AI as central to CVS’s future, with $20 billion committed over a decade and concrete operational savings already realized.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be monitoring (1) the pace of GLP-1 adoption and the expansion of consumer-facing offerings, (2) the impact of AI-driven platforms like Health100 and Haio on efficiency and consumer engagement, and (3) progress on Aetna margin recovery and group Medicare Advantage renewals. We will also be watching for updates on 340B program headwinds and Caremark membership changes as contract dynamics evolve.
CVS Health currently trades at $93.52, down from $104.42 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
